12/10/2017 20:50:00

CAPS® to Showcase Latest 503B Quality Assurance Capabilities and Expansion Plans at Health Connect Reverse Expo – Fall Hospital Pharmacy Conference

IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS®), will showcase its sustained commitment to improving patient safety at the 2017 Health Connect Conference in Chicago, IL, Oct. 16-18.

At booth #508, CAPS representatives will introduce the company’s latest 90-Day Beyond Use Dating (BUD) quality assurance offering for pre-filled syringes and other products, which is designed to improve the waste reduction process. This initiative further complements CAPS’ current extended BUD offerings. 

CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act. During the conference, CAPS will highlight its Test, Hold and ReleaseSM (THR®) program, which is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for 100% cGMP release testing for sterility, potency, and endotoxin prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.

“Our existing high quality standards are strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that 100% release testing from our 503B facilities is the only way to assure the level of quality demanded by our customers.”

CAPS was among the first outsourcing admixture pharmacies in the nation to fully adopt release testing.

“CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment,” said Koch. “Our goal is to provide our customers with programs such as THR, and extended BUD to help them focus on improving patient care.” 

To further underscore its commitment to servicing its customers and expanding its sterile compounding outsourcing services in the U.S., CAPS will open a new 250,000 square-foot, state-of-the-art facility in Phoenix, AZ, which is expected to open in the summer of 2018. The new facility will be registered with the FDA as a 503B outsourcing facility, to distribute compounded sterile preparations. CAPS has two existing 503B facilities located in San Diego, CA and Allentown, PA.

“With the opening of our third 503B facility, CAPS will enhance productivity and increase capacity, while serving as an economic boost to the local and state economy,” said Tom Wilverding, President of CAPS. “When fully operational the CAPS facility will create nearly 400 new jobs including opportunities for pharmacists, pharmacy technicians, chemists, microbiologists, and other support personnel.”

About B. Braun

B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

About CAPS

CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS currently has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.CAPSpharmacy.com.

Contact:    

Todd Jones

Central Admixture Pharmacy Services, Inc. 303.744.7713

Todd.Jones@CAPSpharmacy.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jun
I:SP500
  Hejsa alle sammen   Konjunktur: Ifølge vedlagte teoretiske model omkring de ledende indikatorer be..
48
20 Jun
GEN
Et gammelt indlæg:   Hvis man kigger lidt tilbage i tiden og ser på de kvartalsvise resultater, så l..
36
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
20 Jun
GEN
Hold da kæft, du er godt nok en sur (gammel ?) mand......
16
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
19 Jun
I:SP500
Trump har bedt det amerikanske handelsministerie om en liste over kinesiske varer for 200 mia USD, s..
12
18 Jun
BAVA
Dvs de bør være der indenfor 9 børsdage... Hvis disse data gentager det som er kommet frem indtil nu..
12
23 Jun
 
USA blev løftet ud af recession under Obama. Punktum. Økonomien kørte fint da Trump blev valgt og er..
11
20 Jun
NOVO-B
Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenl..
11
18 Jun
VWS
I begyndelse af året havde grædekonerne kronede dage, hvad angår ordreindtag. Det har li'som ændret ..
11

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
2
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
3
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
4
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 06:06:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-24 07:06:00 - 2018-06-24 06:06:00 - 1000 - Website: OKAY